Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
Nothing Generic About This ETF's Long-Term Outlook
Allergan Again A Core Holding At UBS
Biotech Daily Digest: Pfizer Beats, Eagle Sues The FDA, Updated View On Relypsa After Big Debt Deal (Seeking Alpha)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
May 2016Credit SuisseInitiates Coverage onNeutral
May 2016Morgan StanleyMaintainsOverweight
Feb 2016Wells FargoInitiates Coverage onOutperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!